sb 216763 has been researched along with Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XL; Dai, HY; Ding, XJ; Guo, NF; Peng, WS; Zhang, Y; Zhang, YD; Zhou, QL | 1 |
| Allen, DA; Bauer, I; Collin, M; Dugo, L; Foster, SJ; Louhelainen, M; Mervaala, EM; Patel, NS; Thiemermann, C; Yaqoob, MM | 1 |
2 other study(ies) available for sb 216763 and Kidney Diseases
| Article | Year |
|---|---|
SB-216763, a GSK-3β inhibitor, protects against aldosterone-induced cardiac, and renal injury by activating autophagy.
Topics: Aldosterone; Animals; Autophagy; Cytokines; Fibrosis; Glycogen Synthase Kinase 3 beta; Heart Diseases; Indoles; Inflammation; Kidney Diseases; Male; Maleimides; Rats; Rats, Wistar | 2018 |
GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat.
Topics: Alanine Transaminase; Aminophenols; Animals; Aspartate Aminotransferases; Blotting, Western; Cells, Cultured; Creatine Kinase; Creatinine; Endotoxemia; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Kidney Diseases; Lipase; Lipopolysaccharides; Liver; Male; Maleimides; NF-kappa B; Peptidoglycan; Phosphorylation; Polysaccharides, Bacterial; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Thiadiazoles | 2005 |